Herborium Announces the New International Distribution
December 09 2010 - 9:50AM
Marketwired
Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a
Botanical Therapeutics™ company, today announced that it is
partnering with the retail division of the major Portal Technology
provider, Adrecom, to distribute its unique botanical therapeutic,
AcnEase®, for Acne and Rosacea (www.acnease.com) in Israel with
expected $500,000 plus in revenues over next 36 months. This
partnership furthers our efforts to become the worldwide leader in
Natural Acne Treatment and Preventative Therapy.
Israel is a very attractive market for AcnEase. Its population
of 24 million have maintained the highest per-capita income in the
region (close to $29,000) and only 6.2% unemployment rate. In
addition, according to the Euromonitor International, Israel
maintains a 4% yearly growth, and 2009 and 2010 witnessed a
continuous increase in sales of health supplements and
nutraceuticals, "as awareness of its positive benefits increases
among Israeli consumers." Health supplements in Israel represent a
large potential for near-term growth as 30% of households in Israel
consume natural medicinal products and market penetration rates are
rising.
"The opportunity for AcnEase sales in Israel is considerable,"
commented Dr. Agnes Olszewski, Herborium's president and chief
executive officer. "We anticipate meeting the regulatory
requirements necessary to enter the market within the next three
months. The partners will commit the funds necessary to meet those
requirements as well as the associated marketing costs. AcnEase is
especially attractive to Israeli consumers as it is not only
efficacious and all natural, but also suitable for all types of
skin pigmentation."
Herborium expects to enter the market by the end of the second
quarter of 2011 and market projection for the first 12 months call
for sales of between $100,000 to $150,000, with $300,000 projected
within 24-36 months. The arrangement is not exclusive until sales
performance milestones are met.
The new international distribution arrangements are but one
example of Herborium's "Road-to-Market" Strategy calling for
revenues projections of $7.5 Million, as detailed ("Road-to-Market"
Strategy), and with an ultimate goal to eventually capturing 1% of
the Global Natural and Alternative Treatments Market.
About Herborium Group, Inc. Herborium
Group, Inc., a Botanical Therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanically based
medicinal products to consumers and healthcare professionals. The
Company's business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. For more
information, please visit www.herborium.com and
www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time they are issued, and we disclaim any
obligation to update or alter forward-looking statements as the
result of new information or future events. The Company urges
investors to review the risks and uncertainties contained within
its filings with the OTC Markets and/or Securities and Exchange
Commission.
Company Contact: Steve Haag Investor Relations (832)
413-6206
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From May 2024 to Jun 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2023 to Jun 2024